Vivoryon Therapeutics N.v. · EURONEXT:VVY
Vivoryon Therapeutics — FY2021 Earnings Presentation
11 slides from Vivoryon Therapeutics's earnings presentation, Apr 28, 2022
Slide 1: Full Year 2021 Results Webcast and Conference Call
FULL YEAR 2021 RESULTS WEBCAST AND CONFERENCE CALL April 28, 2022 |Vivoryon Therapeutics N.V.
Slide 2: Important Notice and Disclaimer
IMPORTANT NOTICE AND DISCLAIMER This document has been prepared by Vivoryon Therapeutics N.V. (the “Company” or “We”) strictly only for discussion purposes. This document does not constitute or form part of any offer or invitation to sell or issue, any offer or inducement or invitation or commitment
Slide 3: Vivoryon's Approach to Overcoming the Challenges of AD Drug Development
VIVORYON’S APPROACH TO OVERCOMING THE CHALLENGES OF AD DRUG DEVELOPMENT Oral small molecule inhibitor varoglutamstat targeting multiple hallmarks of AD QPCT/L AS KEY TARGET IN AD VAROGLUTAMSTAT TARGETS UPSTREAM PATHOGENESIS High unmet medical need in AD despite recent advances CCL2 Abeta Despite app
Slide 4: 2021 Clinical Portfolio Highlights
2021 CLINICAL PORTFOLIO HIGHLIGHTS ◆ Fast Track designation granted by the U.S. Food and Drug Administration (FDA) for varoglutamstat as an investigational oral small molecule medicine for the potential treatment of early AD ◆ VIVA-MIND U.S. Ph 2a/b study of varoglutamstat initiated and currently en
Slide 5: 2021 Corporate Development Highlights
2021 CORPORATE DEVELOPMENT HIGHLIGHTS ◆ Strategic regional licensing partnership with Simcere to develop and commercialize N3pE amyloid-targeting medicines to treat AD in Greater China; Vivoryon to receive combined upfront and milestone payments of up to US$ 565 million plus double-digit royalties o
Slide 6: Clinical Development Strategy
CLINICAL DEVELOPMENT STRATEGY Clear Path To Potential Regulatory Approval Extensive Phase 1 and Phase 2 trials Pivotal study or Phase 2b VIVIAD accelerated approval Assessment of safety, tolerability and FDA Fast Track designation efficacy in 250 Patients MCI and mild AD granted in 2021 Two possible
Slide 7: Varoglutamstat Clinical Milestones
VAROGLUTAMSTAT CLINICAL MILESTONES 2022/2023 outlook Phase 2b study in 250 patients Phase 2a/b study in 414 patients ◆ Clinical Trial Application with MCI/mild AD with early AD approved in China Endpoints: safety, attention/working Endpoints: safety, ABC scores/ ◆ Ph 1 study planned for memory, NTB,
Slide 8: Condensed Statement of Profit and Loss
CONDENSED STATEMENT OF PROFIT AND LOSS In €k 2021 2020 % Gross profit 9,196 0 Research and development expenses (17,452) (13,210) 32 % General and administrative expenses (4,549) (2,807) 62 % Operating loss (12,798) (16,011) (20) % Finance result 575 (499) >100% Income taxes (432) 0 Net loss for per
Slide 9: Key Financial Figures
KEY FINANCIAL FIGURES In €k Dec 31, 2021 Dec 31, 2020 Cash and cash equivalents 14,661 26,306 Total assets 24,520 29,751 Total equity 16,557 26,221 Shares (number) 20,050,482 19,975,482 In €k 2021 2020 Cash flows used in operating activities (11,257) (14,012) Cash flows used in investing activities
Slide 10: Q&A
Q&A
Slide 11: Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Munich Franz-Josef-Delonge-Str. 5 81249 München Germany Halle (Saale) Weinbergweg 22 06120 Halle (Saale) Germany info@vivoryon.com +49 (0)345 555 99 00 www.vivoryon.com